Our companyHome Our Company Who we are
- Who we are
Minoryx is a clinical-stage biotech company focused on the discovery and development of novel therapies for severe, orphan genetic diseases of the central nervous system (CNS) with high unmet medical need.
Our lead program is a novel, selective and differentiated brain penetrant PPAR gamma agonist (leriglitazone), which is currently in clinical development for X-ALD and other CNS diseases. Leriglitazone demonstrated strong preclinical proof-of-concept in relevant animal models of disease and successfully completed phase 1 clinical trials. Leriglitazone was evaluated in a phase 2/3 study in adrenomyeloneuropathy (AMN) in EU and US with an open-label extension still ongoing. Leriglitazone significantly reduced the progression of cerebral lesions and myelopathy symptoms. The marketing authorization application (MAA) for adult male X-ALD patients is under review by the EMA and the launch preparations in the EU are underway. Also, discussions are currently ongoing with the FDA to define the next steps for its US approval path. In parallel, a separate study is ongoing on pediatric cALD patients in EU.
Additionally, a proof of concept study in Friedreich’s Ataxia (FRDA) showed clinical benefit in this population and a phase 3 confirmatory study is under discussion with the EMA and FDA.
Leriglitazone has been granted Orphan Drug Designation for X-ALD and for FRDA by both the European Commission (EC) and the US Food and Drug Administration (FDA), as well as, Fast Track for X-ALD from the US FDA. In addition, leriglitazone has been designated as Rare Pediatric Disease Designation by FDA for both X-ALD and FRDA.
- Our values and how we make a difference:
One of the biggest assets of the company is our team, a group of professionals fully committed to the making new therapies available for patients suffering from severe, orphan diseases.
We are dedicated to bringing new hope for people suffering from rare diseases, especially children and their families.
Innovation & Dynamism:
We innovate by exploiting state-of-the art technologies. We form synergistic drug development partnerships and provide an environment which fosters creativity and open-mindedness.
We are making strides to provide life-changing treatments for diseases with high unmet medical needs.
- TecnoCampus Mataró-MaresmeHeadquartersOfficesinfo@minoryx.com +34 93 544 14 66Av. Ernest Lluch 32
08302 Mataró (Barcelona) SpainBiopark Charleroi Brussels SouthBelgian R&D SiteOfficesinfo@minoryx.com +32 (0)2 342 08 03Ave. Jean Mermoz 32
6041 Gosselies (Charleroi) Belgium